Differential and unique patterns of synaptic miRNA expression in dorsolateral prefrontal cortex of depressed subjects

Yuta Yoshino1, Bhaskar Roy1 and Yogesh Dwivedi1

Altered synaptic plasticity is often associated with major depressive disorder (MDD). Disease-associated changes in synaptic functions are tightly correlated with altered microRNA (miRNA) expression. Here, we examined the role of miRNAs and their functioning at the synapse in MDD by examining miRNA processing machinery at synapse and sequencing miRNAs and analyzing their functions in synaptic and total tissue fractions obtained from dorsolateral prefrontal cortex (dIPFC) of 15 MDD and 15 matched non-psychiatric control subjects. A total of 333 miRNAs were reliably detected in the total tissue fraction. Multiple testing following the Benjamini–Hochberg false discovery rate (FDR) showed that 18 miRNAs were significantly altered (1 downregulated 4 and 13 downregulated; p < 0.05) in MDD subjects. Out of 351 miRNAs reliably expressed in the synaptic fraction, 24 were uniquely expressed at synapse. In addition, 8 miRNAs (miR-215-5p, miR-192-5p, miR-202-5p, miR-19b-3p, miR-423-5p, miR-219a-2-3p; miR-511-5p, miR-483-5p) showed significant (FDR corrected; p < 0.05) differential regulation in the synaptic fraction from dIPFC of MDD subjects. In vitro transfection studies and gene ontology revealed involvement of these altered miRNAs in synaptic plasticity, nervous system development, and neurogenesis. A shift in expression ratios (synaptic vs. total fraction) of miR-19b-3p, miR-376c-3p, miR-455-3p, and miR-337-3p were also noted in the MDD group. Moreover, an inverse relationship between the expression of precursor (pre-miR-19b-1, pre-miR-199a-1 and pre-miR-199a-2) and mature (miR-19b-3p, miR-199a-3p) miRNAs was found. Although not significantly, several miRNA processing enzymes (DROSHA [95%], DICER [17%], TARBP2 [38%]) showed increased expression patterns in MDD subjects. Our findings provide new insights into the understanding of the regulation of miRNAs at the synapse and their possible roles in MDD pathogenesis.

INTRODUCTION

Major depressive disorder (MDD) is one of the most debilitating mental disorders worldwide with a lifetime prevalence of 10.8% [1]. Despite significant effort, the pathophysiology of MDD is not well understood. Some of the most prominent findings in MDD are reduced brain plasticity, loss of synaptic connections, and impaired synaptogenesis [2], which could be the consequence of altered molecular pathways and underlying gene regulatory networks [3]. Recently, microRNAs (miRNAs), members of small noncoding RNA families, have received much attention for their unique ability to control complex gene regulatory networks [4, 5]. Mammalian miRNA biogenesis is a programmed pathway which starts canonically with the transcription of a primary transcript (pri-miRNA) by RNA polymerase II/III in nuclei. Pri-miRNAs are ~1 kb in size and contain typical stem-loop structure. With the help of a microprocessor complex (primarily consisting of DROSHA and DGCR8), pri-miRNAs are cropped into smaller hairpin structures (65nts) called precursor miRNAs (pre-miRNAs). Following canonical biogenesis pathway, pre-miRNAs are exported into the cytosol in an Exportin-5 (XPO5)/Ran-GTP-dependent manner and further processed by RNase III DICER. Finally, mature miRNAs are incorporated into the RNA-induced silencing (RISC) complex, which regulates the expression of target genes via translational blockage, transcript degradation, or deadenylation [5]. miRNAs can quickly respond to environmental changes and may generate a highly regulated gene network(s) that can profoundly impact behavior [6]. Our laboratory has previously shown the role of miRNAs in adaptive and maladaptive response to stressful stimuli, a critical factor in MDD pathogenesis [7]. In addition, the role of miRNAs in synaptic plasticity, under both neurodevelopmental and pathogenic conditions, is well documented [8]. Our post-mortem brain studies in MDD subjects have shown network-level changes in miRNAs that can target downstream genes involved in neural plasticity and synaptic functions [9]. Interestingly, a possible role of miRNA processing machinery locally at the synapse has been suggested for activity-dependent changes in miRNA expression. In this regard, it has been shown that not only is miRNA maturational machinery available at the synapse [10], but that miRNA biogenesis can occur in the postsynaptic densities (PSDs) near synapse [10–12]. Also, it has been shown that a subset of miRNAs is expressed at a higher level in synaptic fraction than the whole cell lysate isolated from mouse brain [11], which could be the result of an active mobilization of pre-miRNAs and their cleavage into mature miRNAs near synapse with the help of DICER, TRBP and other processing molecules [10, 13]. Reports also indicate the role of local synaptic activity in triggering the release...
of certain miRNA from miRNA mediated masking, which might facilitate local protein translation in synaptic projections [10, 13–15]. Although it is a growing area of interest, not much has been studied to understand the role of synaptic miRNAs and their underlying regulation in neuropsychiatric disorders.

In the present study, we determined differential expression patterns and functions of miRNAs in synaptic and total tissue fractions isolated from dorsolateral prefrontal cortex (dIPFC) of MDD subjects and matched healthy controls. We chose dIPFC because of its critical role in MDD pathogenesis [16]. For example, dIPFC receives input from specific sensory cortices and is densely interconnected with premotor areas and is involved in executive and cognitive functions such as intention formation, goal-directed action, and attentional control [17]. Additionally, imaging studies reveal functional role of dIPFC where hypoactive resting state is associated with MDD pathogenesis [18]. dIPFC is also involved in activating hypothalamic-pituitary-adrenal (HPA) axis in response to stress as well as in negative feedback regulation [19, 20]. Synapse related gene expression changes have also been reported in dIPFC of MDD subjects [21]. Next, we examined the enrichment of miRNAs in the synaptic fraction by comparing total and synaptic miRNA expression ratios. Unique miRNA expressions were determined by comparing total and synaptic miRNA expression patterns. In addition, we examined the expression of select pre-miRNAs and corresponding mature miRNAs, miRNA processing machinery, and target genes in the synaptic fraction. In vitro analyses were performed to determine the function of select miRNAs. Our overall findings suggest that in MDD brain, miRNA expression may be locally regulated at synapse that might have a significant impact on downstream gene regulatory network(s) involved in synaptic functions.

**MATERIALS AND METHODS**

A detailed methodology is discussed in the accompanying supplemental section. The study comes under exemption 4 and was approved by the Institutional Review Board of the University of Alabama at Birmingham.

Human postmortem brain studies

*Subjects.* The study was performed in dIPFC (Brodmann’s area 46) of 15 MDD and 15 non-psychiatric control subjects (referred hereafter as controls) obtained from Alabama Brain Collection and Maryland Brain Collection programs. Detailed tissue dissection was provided in the supplemental section. The demographic and clinical characteristics of subjects are shown in Table S1. The psychiatric diagnoses were determined by the method of psychological autopsy as detailed in the supplemental section. After receiving written informed consent, at least one member/informant from the family underwent an interview based on the Diagnostic Evaluation After Death (DEAD) [22] and the Structured Clinical Interview for the DSM-V (SCID) [23]. Both cases and controls were characterized by the same psychological autopsy method. There were no significant differences in age, postmortem interval (PMI), and brain pH between MDD and control subjects (Table S1). MDD group had 7 males and 8 females, whereas control group had 8 males and 7 females. Out of 15 MDD subjects, 6 showed positive antidepressant toxicity, 3 had alcohol abuse, and 1 had a history of drug abuse. None of the control subjects had any history of alcohol or drug abuse and were not taking any antidepressants.

**Synaptosome preparation and characterization.** Synaptosomes were isolated by the modified method of Smallheiser and Collins [24] and Lugli et al. [12]. Briefly, 100 mg tissue was homogenized using pestle (total fraction) and centrifuged at 20,000 × g for 20 min at 4 °C. The supernatant (S fraction) and pellet were collected. Afterward, sucrose gradient centrifugation was conducted to obtain purified synaptosomes using the resuspended pellet. Twenty micrograms of protein for each isolated fraction (total, S, and synaptic) were subjected to SDS-PAGE (sodium dodecyl sulfate based polyacrylamide gel electrophoresis) as described in the supplemental section. PCNA, PSD95, and Synapsin I antibodies were used to validate synaptosome fraction preparation as detailed in the supplemental section.

**Isolation of RNA from total and synaptosome fractions.** TRIzol® (Invitrogen, Grand Island, NY, USA) was used to isolate RNA as described earlier [7]. RNA purity was checked by Nanodrop (260/280 nm; cutoff ≥ 1.8) and their integrity by agarose gel electrophoresis (Fig. S1A).

**Library construction and sequencing of miRNAs.** miRNA based transcriptomic expression in synaptosomes was measured using next-generation sequencing (NGS) platform. Total RNA prepared from purified synaptosomes was used to prepare the miRNA sequencing library for each sample. Briefly, the NGS library was prepared using NEB Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs, Ipswich, MA, USA), which included the following steps: (1) 3′-adapter ligation by T4 RNA ligase 2; (2) 5′-adapter ligation by T4 RNA ligase; (3) cDNA synthesis by reverse transcription; (4) low cycle PCR amplification of the library DNA; and (5) size selection by polyacrylamide gel electrophoresis of 135–155 bp PCR amplified fragments (corresponding to ~15–35nt small RNAs). After the libraries were prepared for each sample, they were quantified with Agilent 2100 Bioanalyzer and their qualities were checked. Next, the DNA fragments in the libraries were denatured with alkaline treatment (0.1 M NaOH) to generate single-stranded DNA molecules, captured on Illumina flow cells, amplified in situ, and finally sequenced for 51 cycles on Illumina NextSeq 500 (Illumina, San Diego, CA, USA) according to the manufacturer’s instruction. Raw sequencing data generated, that passed the Illumina chastity filter, were used for further analysis.

**Bio-computational analysis of miRNA sequencing data.** The raw sequencing reads were removed from the adapter sequence as the trimmed reads by cutadapt software. Reads ≥ 15 bps were aligned to miRNA sequences in miRBase 21 reference database by bowtie software [25]. The reads aligned to unique location in the reference genome with no more than 2 mismatches were considered as uniquely aligned reads. Raw read counts were normalized as counts per million mappable reads (CPM) using Trimmed Mean of M-values (TMM) method in edgeR software package [26]. Any CPM values < 1 were not included in the analysis. Differential expression between groups was analyzed by edgeR using generalized linear model (glm) with empirical Bayes moderation [27].

**In silico prediction of miRNA target genes.** In silico prediction of miRNA targets were performed either in batches or individually. A list of miRNAs in batches was used to predict their putative targets following miRWalk v2.0 [28]. On the other hand, the putative targets of individual miRNAs were predicted using TargetScan v7.2 (http://www.targetscan.org/vert_72/)) and miRDB (http://mirdb.org/) databases [29].

Determinations of uniquely expressed miRNAs in synaptic fraction and their relative expression ratios (synaptosomal fraction vs. total fraction). Uniquely expressed miRNAs were defined as those detected in synaptosomes, but not in the total fraction based on the identification criteria discussed in the supplemental section. The expression ratio (synaptosomal/total fraction) of each miRNA was determined independently in control and MDD subjects using normalized CPM values from miRNA-seq data. Subsequently, these values were used to compare synaptosome/total fraction ratios between control and MDD subjects.
Functional annotation of miRNA targets following Gene Ontology (GO) prediction. GO analysis was done independently on predicted targets of miRNAs which were found to be uniquely expressed in synaptosomes as well as those that were significantly dysregulated in synaptic fractions of MDD subjects. To obtain a consensus list of predicted targets, in silico prediction algorithm from 8 different prediction programs (miRWalk, Microt4, miRandA, miRDB, Pictar2, PITA, RNA22, and Targetscan) was used. Next, a common list of target genes, shared by any seven for uniquely expressed and six for significantly dysregulated miRNAs, was used. For miRNAs that were uniquely associated with synaptosomes, the consensus list of predicted target genes was used in standalone Cytoscape program to perform GO analysis using ClueGO plugin. Display pathways were selected with p ≤ 0.05. Clustering was done based on common functionality of genes enriched for specific term. The kappa score was set at 0.4 to define the term-term relationship (i.e., edges between the nodes). Genes involved in more than one function were represented with multiple color combination. For synaptosomal miRNAs that were significantly altered in MDD subjects, the consensus list of predicted target genes was used to predict GO terms using the ShinyGO program [30]. The prediction analysis was done following an FDR corrected p value cutoff (p = 0.05) to determine the gene set enrichment in biological processes (BP) and cellular components (CC) categories separately. In BP, 30 most significant terms were used to plot the network with edge cutoff p = 0.05, whereas, in CC, the connected nodes were presented with 40 most significant terms with edge cutoff p = 0.03. In each category, the enriched terms were used to create networks where nodes were presented with terms and connected with edges. If two nodes were connected, then they shared 20% (default) or more genes. Bigger nodes represented larger gene sets, while thicker edges represented more overlapped genes. Separately, Ingenuity Pathway Analysis Software (IPA; Qiagen, Valencia, CA, USA) was used to predict the functional role of miRNAs differentially expressed in total fraction of MDD subjects. Modules for functional enrichment of predicted targets deciphering their role in the canonical pathways, molecular networks, and disease pathways were created using Fisher’s exact test and p value ≤ 0.05. All visualizations from IPA analysis were made using customized R scripts.

qPCR-based miRNA and mRNA-specific gene expression. Primer sequences and qPCR protocols are detailed in the supplemental section (Table S2). miRNA-specific cDNA was synthesized using poly(A)-tailing method whereas mRNA-specific cDNA synthesis was performed with the Oligo (dT)18 priming method (Invitrogen, USA). qPCR-based relative transcript quantification of all genes was determined with EvaGreen chemistry (Applied Biological Materials, Canada). Pre-miRNA primers were made according to their base sequences (miRBase, http://www.mirbase.org/). Forward primers spanned over the DICER cleavage site and the reverse primer spanned towards 3′ end to make a long product. U6 was used as a normalization for miRNA transcript quantification, whereas geometric means of GAPDH, ACTB, and ribosomal 18S RNA were applied to quantify synaptosomal mRNAs, pre-miRNAs, and genes associated with miRNA maturation (i.e., DICER1, TARBP2, DROSHA, and AGO2). Fold changes were calculated by Livak’s ΔΔCt method [31].

In vitro cell line-based studies. For in vitro experiments, SH-SY5Y neuroblastoma cells (ATCC CRL2266) were used. Double-stranded RNA oligos (miR-19b-3p mimic [C-300483-03-0002], hairpin inhibitor (IH-300489-05-0002); miR483-5p mimic (C-301107-01-0002), hairpin inhibitor (IH-301107-02-0002), miR-511-5p mimic (C-300752-03-0002), and hairpin inhibitor (IH-300752-05-0002) were purchased (Dharmacon GE Life Sciences, USA) and used. RNA oligos were transfected into SH-SY5Y cells and harvested 48 h post-transfection for target gene expression analysis. The study was replicated in two independent batches of cell lines.

Statistical analysis Statistical analyses were conducted using SPSS software (V.25; IBM, USA). Shapiro-Wilk test was used to assess normality of the data. Only data that were normally distributed were used. The differences in age, PMI, and brain pH were assessed by independent-sample t-test. Effects of gender, drug abuse, alcohol abuse, and antidepressant medications were analyzed by Fisher’s exact test. The differences in miRNA expression, mRNA expression, and miRNA based relative expression ratios between control and MDD subjects were analyzed using independent-sample t-test. The differences in miRNAs and target gene expression among vehicle, mimic, and hairpin inhibitors were assessed by one-way analysis of variance (ANOVA) followed by post-hoc corrections. Correlations of miRNA expression and miRNA ratios of synaptosomal/total fraction with covariates were conducted with Pearson correlation coefficient. Statistical significance was set at 95% level (p ≤ 0.05).

RESULTS

miRNA changes in total and synaptic fractions of MDD subjects Initially, the synaptic fraction prepared from human dIPFC was characterized. As shown in Fig. S1B, synapsin I was present in total, supernatant, and synaptosomal fractions; PSD-95 was highly enriched in the synaptosomal fraction and was absent in the supernatant fraction. On the other hand, nuclear marker PCNA was absent in the synaptic fraction but was present in the total and supernatant fractions. These results are similar to those reported earlier in mouse [10, 12] and human [32] brain.

Both total and synaptic fractions were used for miRNA sequencing separately. In the total fraction, 333 miRNAs were reliably detected following the cleansing of normalized sequencing data. Figure 1a shows an expression heatmap demonstrating the normalized expression levels of select miRNAs following a hierarchical clustering method. Differentially expressed miRNAs in MDD group are shown in Fig. 1b as a volcano plot. Of 333 miRNAs, 4 miRNAs were significantly upregulated and 14 miRNAs were significantly downregulated in MDD subjects compared to control subjects (Fig. 1c).

miRNA-seq results in the synaptic fraction showed the expression of 351 miRNAs based on the criteria discussed in the supplemental section. Selected miRNAs expressed in the synaptic fraction are shown in a heat map following a hierarchical clustering method (Fig. 2a). Following the average linkage clustering algorithm, a dendrogram was constructed to demonstrate the expression similarities (Fig. 2a). Of 351 miRNAs expressed in the synaptic fraction, 6 miRNAs (miR-215-5p, miR-192-5p, miR-202-5p, miR-19b-3p, miR-423-5p, miR-219a-2-3p) showed significant upregulation (>30%) and 2 miRNAs (miR-511-5p, miR-483-5p) showed significant downregulation (<50%) in MDD subjects (Fig. 2b).

Next, we determined miRNAs that were uniquely associated with synaptic fraction. It was observed that 24 miRNAs were exclusively expressed in the synaptic fraction and were absent in the total fraction (Fig. 3a). In the pool of uniquely expressed miRNAs, 7 showed >20% upregulation (miR-1294, miR-1914-5p, miR-196a-5p, miR-2276-3p, miR-302b-3p, miR-365b-5p) and 6 showed >20% downregulation (miR-449-5p, miR-512-3p, miR-517c-3p, miR-519d-3p, miR-520a-3p, miR-550a-3p) in the MDD group; however, only miR-202-5p showed significant change, which was highly upregulated (>9 fold) in the MDD group (Table S3). A phenogram (Fig. S3) was drawn to show the relative localization of uniquely expressed synaptic miRNAs (with 20% change) on different chromosomes. The blue (up) and red (down)
colors show miRNAs found with up and downregulated expressions respectively.

GO and path analysis based on predicted target genes of MDD associated miRNAs in the total fraction
The GO analysis of biological pathways based on in silico predicted target genes of miRNAs from total fraction indicated that they were primarily associated with multiple synaptic related GO terms, including axon, dendrites, neuron projection, synaptic vesicle membrane, pre and post-synapse, and glutamatergic synapse (Fig. 1d). The IPA results of canonical and disease pathways are shown as bubble plot (Fig. 1e, f). In canonical pathway, several cellular signaling terms appeared that are highly relevant to depression, such as glutamatergic, ERK/MAPK, neuregulin, estrogen receptor, PI3K, telomeres, as well as axon guidance. The result of disease pathway also indicated that these altered miRNAs were related to nervous systems and psychological disorders (Fig. 1f).

GO and path analysis based on predicted target genes of miRNAs in the synaptosomal fraction
When GO analysis of 8 significantly altered miRNAs in the synaptosomes of MDD subjects was determined, several important biological pathways and cellular components appeared. As can be seen in Fig. 2c, d, the clustered biological functions were plotted into networks to represent their relatedness. Biological process-based network mapped the term nervous system development as a hub, which was central to other connected terms associated with neurogenesis, neuronal development, differentiation, neuron projection, and morphogenesis. On the other hand, cellular component-based network analysis projected changes in gene functions related to synaptic and somatodendritic compartments. Significant enrichment was also noted for neuronal functions central to morphogenetic changes, including growth cone, dendritic tree, neuron projections, and distal axonic growth. Genes enriched in each category, under biological process and cellular components, are detailed in Tables S4 and S5.
Following GO enrichment analysis several neuronal function-related ontology terms were identified based on predicted targets of 24 uniquely expressed miRNAs from synaptic fraction (Fig. 3a). Top significantly enriched GO terms were associated with neuron projection, neuron development, neuron fate commitment and dendritic development (Fig. 3b). Additionally, network analysis based on the target genes of these miRNAs showed the enrichment of GO terms central to transcriptional regulation (Fig. 3c) which were found to impact RNA metabolism besides influencing neuronal functions.

In silico prediction and validation of target genes using in vitro cell model
We randomly selected miRNAs (miR-19b-3p, miR-483-5p, and miR-511-5p) from the list of significantly altered MDD associated miRNAs in synaptosomes (Fig. 2b) and validated their functions in vitro with target gene expression (Fig. 4). Based on TargetScan v7.2 and mirDB databases, several predicted target genes related to neuronal functions were identified. These included: CSRD3, CHP1, CHST7, CYBS616D1, FUT9, N6AMT1, SEL1L3 for miR-19b-3p; CSAR1, CCDC9, C33CL1, ELK1, FOXO3, HBGFI, IRF1, NFAM1, MAP2K3, TMEM98 for miR-483-5p; and CD68, DISC1, ELK1, IL17RA, IRF2, PHLDB1, TAB2 for miR-511-5p. The target prediction profile for each miRNA (based on in-silico analysis) is presented in Tables S6, S7, and S8. Significant expression changes of these target genes were confirmed from RNA sequencing determined in the same fraction (Tables S6–S8, also see Supplemental section for detailed RNA sequencing methods and analysis). The functional relationship of these genes with corresponding miRNAs (miR-19b-3p, miR-483-5p, and miR-511-5p) was determined by in vitro transfection assay. As shown in Fig. 4, the expression of these genes had an inverse relationship with their corresponding miRNAs. Significant downregulation was found for CSRD3 (43%; p < 0.001), CHST (29%; p = 0.002), N6AMT1 (49%; p = 0.004), and SEL1L3 (34%; p < 0.001) genes in miR-19b-3p mimic transfected cells. Similarly, significant lower expression of CCDC9 (43%; p = 0.006), C33CL1 (51%; p = 0.001), ELK1 (32%; p = 0.011), FOXO3 (39%; p = 0.001), MAP2K3 (51%; p < 0.001), and TMEM98 (33%; p = 0.030) was noted in miR-483-5p mimic transfected cells. ELK1 gene was found to be repressed (33%; p < 0.001) in miR-511-5p mimic transfected cells.
Expression of miR-19b-3p hairpin inhibitor significantly unmasked the repressive effect from SEL1L3 expression mimic transfected cell. Similar changes were noted for CCDC9 and MAP2K3 expressions under the influence of miR-483-5p hairpin inhibitor and ELK1 expression under the influence of miR-511-5p. Conversely, significant upregulation was found for CSAR1 (125%; \( p < 0.001 \)) in miR-483-5p mimic and PHLDB1 (84%; \( p = 0.001 \)) in miR-511-5p mimic transfected cells. However, this trend was not followed by other target genes such as CHP1, CYB56D1, and FUT9 for miR-19b-3p mimic; HBGEF, IRF1, and NFAM1 for miR-483-5p mimic; and, CD68, DISC1, IL17RA and IRF2 for miR-511-5p mimic transfected cells.

Shift in expression ratios of synaptic vs. total miRNAs A total of 326 miRNAs were commonly expressed in total and synaptosome fractions. Individual miRNAs had a wide range of relative ratios, which was estimated by their expression in control group (Fig. S2). The median synaptic enrichment ratio across all miRNAs was 1.01, with 31.9% of sequences showing enrichment >1.5-fold (19.3% >2-fold) and 32.2% showing depletion >1.5-fold (16.9% ≥2-fold). The highest ratio was found for miR-1908-5p, which was 7.5-fold more abundant in synaptosomes than in total fraction. On the other hand, the lowest ratio was found for miR-101-3p, which was 5.9-fold less abundant in synaptosomes. The top and bottom 20 miRNAs showing high to low ratios in synaptic vs. total fractions are depicted in Table S9.

When the relative expression ratios of miRNAs between synaptic and total fractions were determined, it was observed that the ratios of miR-19b-3p (\( p = 0.047 \)) and miR-376c-3p (\( p = 0.006 \)) were significantly higher, whereas the ratios of miR-455-3p (\( p = 0.012 \)) and miR-337-3p (\( p = 0.038 \)) were significantly lower in MDD subjects compared to control subjects (Table S10).
addition, 20 miRNAs showed large changes in relative expression ratios in MDD subjects (0.36-5.4-fold); however, they could not reach statistical significance (Table S11).

Expression of miRNA processing enzymes in synaptosomes
qPCR-based expression changes in miRNA processing enzymes were examined in synaptosomes. A trend of increased expression for DROSHA (95%), DICER1 (17%), and TARBP2 (38%) was noted in MDD subjects; however, they were not statistically significant (Fig. S4).

Pre-miRNA expression changes in synaptosomes
In order to examine if mature miRNAs were derived from their respective pre-miRNAs at synapse, 4 miRNAs (miR-19b-3p, miR-199a-3p, miR-455-3p, miR-211-5p) were randomly selected based on their preferential synaptic expression in MDD subjects as mentioned in Fig. 2b, Table S10, and Table S11. The geometric mean of GAPDH, ACTB, and ribosomal 18S RNA, that was used to normalize the data, was not significantly different between MDD and control groups (p = 0.395). Significant changes in the expression of pre-miR-199a-1 (p = 0.036), pre-miR-455 (p = 0.037), and pre-miR-211 (p = 0.030) were noted in MDD subject (Fig. 5). Pre-miR-19b-1, pre-miR-199a-1, and pre-miR-199a-2 had an inverse relationship with their corresponding mature isoforms (miR-19b-3p and miR-199a-3p). On the other hand, miR-455 and miR-211 and their corresponding pre-miRNAs showed changes in the same direction (Fig. 5).

Effects of confounding variables
Significantly altered miRNAs in total and synaptic fractions were evaluated for their association with confounding variables such as age, sex, brain pH, PMI, antidepressant toxicology, and a history of alcohol and drug abuse. All subjects in control and MDD groups were White except one subject in the control group was Black. Also, only one subject in the MDD group had a history of drug abuse. In the total fraction, there were no significant correlations between brain pH and PMI with any of the altered miRNAs. Age had significant positive correlation with miR19a-3p and significant negative correlations with miR-487-3p, miR-136-3p, and miR-376-3p (Table S11). There were no significant differences in any of the miRNAs between males and females (Table S11). Within the MDD group, 6 subjects had antidepressant positive toxicology. A
comparison between those who had positive and negative antidepressant toxicology showed no significant differences in miRNA expression (Table S12). In the MDD group, 3 subjects had a history of alcohol abuse; however, none of the miRNAs showed significant differences when compared with those who did not have a history of alcohol abuse (Table S12).

In the synaptic fraction, age, brain pH and PMI had no significant impact on miRNA expression except for miR-19b-3p which was significantly negatively correlated with age (Table S13). A comparison of males and females showed no significant difference in any of the miRNAs that had altered expression in the MDD group (Table S13). Similarly, antidepressant toxicology did not affect miRNA expression changes in the MDD group (Table S13). A comparison of MDD subjects who had a history of alcohol abuse vs. those who did not also had no significant impact on miRNAs except miR-202-5p which had significantly lower expression in the group showing a history of alcohol abuse (Table S13).

**DISCUSSION**

This is the first study to examine the synaptic enrichment of miRNAs and their possible functions in the brain of MDD subjects. We sequenced miRNAs in both total and synaptic fractions obtained from dIPFC of MDD and control subjects to gain insight into miRNA functions at the level of synapse. We chose to examine dIPFC, since numerous brain imaging studies have identified dIPFC as key brain area involved in MDD [33–36]. Frontal cortical activation during inhibitory control also predicts antidepressant treatment response in patients with MDD [37, 38]. In addition, several postmortem brain studies have implicated dIPFC in MDD pathogenesis [9, 39–42]. Our sequencing results in dIPFC showed 333 miRNAs reliably detected in the total fraction of dIPFC; of them, 18 miRNAs were significantly altered in MDD subjects (4 upregulated and 14 downregulated). On the other hand, a total of 351 miRNAs were detectable in the synaptic fraction; out of them, 24 miRNAs were uniquely associated with synaptic fraction. Eight uniquely associated miRNAs were significantly altered in the dIPFC.
of MDD subjects. In addition, 326 miRNAs were found to be commonly expressed between total and synaptic fractions. Among them, a significant number of miRNAs were either highly enriched or highly depleted in synaptosomes. Also, there were 4 miRNAs that showed a significant shift in their expression ratios between synaptic vs. total fractions in MDD subjects. Additionally, alterations in the expression of pre-miRNAs along with a trend in miRNA maturation and processing enzymes were noted in MDD subjects.

There are broad implications of dysregulated miRNAs in the total and synaptic fractions, alterations in the expression of downstream target genes and their potential functional consequences. When we explored the functions of 18 dysregulated miRNAs in total fraction by GO and IPA analysis with predicted target genes, it was observed that miRNAs that were altered in the total fraction were significantly associated with disruption in a variety of signaling pathways such as PI3K/AKT, ERK/MAPK, Rac, IGFl as well as disruption in cell cycle. These findings are quite consistent with earlier reports showing their role in MDD pathogenesis [43–45]. Canonical pathways, molecular networks, and disease pathways also suggested their roles in various neuronal functions and psychological disorders.

We next determined the function of miRNAs that were significantly altered in the synaptic fraction. We found 6 miRNAs (miR-215-5p, miR-192-5p, miR-202-5p, miR-19b-3p, miR-423-5p, miR-219a-3p) were significantly upregulated and 2 miRNAs (miR-511-5p, miR-483-5p) were significantly downregulated in MDD subjects. Network-based canonical and biological pathways invariably showed their roles in synaptic plasticity. When individual miRNAs were examined, miR-202-5p and miR-192-5p regulated TGF-β signaling pathway [46–48], which has been implicated in MDD pathophysiology [49]. In the mouse model of depression, miR-192-5p rescues cognitive impairment and restores neural functions by enhancing synaptic transmission and neuronal regeneration via Fbn2/TGF-β1 signaling [47, 50]. Using in vitro system, we examined the regulation of select target genes of miR-19b-3p and miR-511-5p which were significantly altered in MDD subjects. Significant downregulation was found in C10orf12, CHST, N6AMT1, and SELT13 genes in miR-19b-3p mimic transfected cells. Among them, N6-methyl-2′-deoxyadenosine methyltransferase (N6AMT1) was associated with the extinction of conditioned fear through the regulation of Bdnf exon IV [51]. On the other hand, CX3CL1 expression was significantly decreased in miR-483-5p overexpressing cells. miR-483-5p plays a critical role in stress-induced depression, as has been demonstrated in our previous study [52]. CX3CL1 is highly expressed in neural cells and is necessary for microglial cell migration with the help of CX3CR1 receptor [53, 54]. CX3CL1 gene induces fractalkine signaling system, which is involved in maturation, activity, and plasticity of developing and mature synapses [55–57] and synaptic repatterning [56]. In fact, Cx3cr1-deficient mice show impairment in the maturation of developing glutamatergic synapse in hippocampus [57, 58]. These findings suggest that miR-483-5p and associated fractalkine signaling via CX3CL1 could be associated with altered synaptic activity reported in MDD subjects [59–61]. miR-511-5p, which was significantly downregulated in MDD subjects, showed an inverse relationship with ELK1 gene in miR-oligo transfected cell culture model. ELK1 is a transcription factor that is activated upon phosphorylation by ERK. Both ERK and ELK1 have been implicated in MDD [62]. ELK1 integrates pathways of NMDA signaling and glucocorticoid receptor system [63, 64]. It has recently been reported that ELK1 mRNA was upregulated in MDD subjects and the failure to reduce ELK1 expression was associated with resistance to antidepressant treatment [65]. Interestingly, ketamine, a rapid antidepressant, induces spine formation through the activation of mTOR signaling in synaptoneurosomes of rat PFC [66] and treatment with inhibitors of ERK diminishes the behavioral effect of ketamine in forced swim test. In mice, ELK-1 overexpression per se produces depressive behaviors; conversely, the selective inhibition of ELK1 activation prevents depression-like behavior and altered synaptic plasticity induced by stress [65].

As mentioned earlier, we found 24 miRNAs were exclusively present in synaptosomes. Interestingly, 14 miRNAs (8 upregulated and 6 downregulated) showed >20% change in their expression in MDD subjects. GO analysis revealed that these miRNAs were involved in neuronal functions including neuronal projections, neuron development, neuron fate commitment, and dendritic development. Genes (TGFβ, CREBBP, LIMK1, GRIN3A, CACNA1A, NOTCH1, PPP3CA, WNTSA, LEF1, CAMK2, and MAP3K2) that were targets of these miRNAs (Table S14) appeared to be quite relevant in MDD pathophysiology [67–71]. We also mapped these exclusive upregulated and downregulated miRNAs with a schematic phenogram model (Fig. S3) to show their relative position on the respective chromosomes. The phenographic representation helps to understand if the similarly regulated miRNA loci are closely positioned on a chromosome. We found that downregulated cluster of 4 miRNAs (miR-512-3p, miR-517c-3p, miR-519d-3p and miR-520a-3p) closely shared physical coordinates on chromosome 19. This is important as it has been shown that generally, homologous miRNAs are prone to appear in clusters based on functional and evolutionary relationships. Also, co-expressed miRNAs are mostly members from a single polycistronic transcript and share common target genes and participate in a particular biological pathway and disease pathophysiology [72]. In fact, we have shown earlier that a large number of miRNAs were downregulated in rat prefrontal cortex which showed resiliency to develop depression, and all showed a blunted response to those that had a susceptibility to depression phenotype. All miRNAs were encoded at a few shared polycistronic loci suggesting that their downregulation was coordinately controlled at the level of transcription. Interestingly, most of these miRNAs have previously been shown to be enriched in synaptic fractions [10, 11]. In the future, it will be interesting to examine the chromosomal organization vis-à-vis genomic clustering of synaptic miRNAs and their functional correlates.

Our study also showed not only a high enrichment of a large number of miRNAs in synaptosomes, but also a shift in miRNAs in synaptic fraction of MDD subjects when ratios of total vs. synaptic miRNAs were determined. It has previously been shown that miRNAs are not only highly enriched near synapse and expressed within dendrites in mammalian brain, but are also regulated in an activity-dependent manner thereby participating in plasticity responses [73]. In fact, pri-miRNAs are present in synaptic fractions and are especially enriched in isolated post-synaptic densities [11]. DROSHA and DGC8R proteins are also expressed at synapse and are tightly associated with pri-miRNAs [11].pri-miRNAs are also transported to synaptic regions and their processing occurs locally near synapses in a regulated fashion [11]. We found a shift in the expression of several miRNAs (e.g., miR-376c-3p, miR-455-3p and miR-337-3p) in the synaptic fraction over total fraction in MDD subjects compared with healthy controls. In addition, miRNAs (e.g., miR-19b-3p and miR-199a-3p) had an inverse relationship with their corresponding pre-miRNAs in the synapse. These findings suggest that miRNA biogenesis/maturatation may be occurring at synapse and the availability of miRNA biogenesis machinery may be disrupted in MDD. Interestingly, we found a trend in the alterations in miRNA processing enzymes DROSHA, DICER1, and TARBP2 in MDD subjects. It has been reported that DICER is located in dendrites and axons [11–13, 74] and pre-miRNAs are cleaved into mature miRNAs near synapses [13, 15, 74]. In addition, we also found that miR-455-3p and miR-211-5p and their corresponding pre-miRNAs were both downregulated. This is quite interesting as it has been reported earlier that biogenesis enzymes need several co-factors to be activated [75]. In addition, specific conditions are necessary to transport and process
individual synapticosomal pre-miRNAs. For example, in addition to DROSHA, the conversion of pre-miR-134 to mature miR-134 in dendrites needs DEAH-box helicase DHX36 binding to its terminal loop [13]. We speculate that the co-factors related to biogenesis enzyme activation and/or transportation of certain pre-miRNAs to synaptosome may not be functional in MDD as was noted for miR-455-3p and miR-211-5p where both pre-miRNA and mature miRNAs were downregulated. Alternatively, we hypothesize that the shift in expression could be due to dysregulated distribution and partitioning of expressed miRNAs between total and synaptic compartments under MDD pathology. Further studies will be needed to confirm these speculations.

In conclusion, our study, for the first time, shows that a large number of miRNAs are synaptically enriched and a pool of miRNAs are uniquely associated with synapse. These synaptic miRNAs are differentially regulated in MDD subjects. In addition, there is a shift in the expression of synaptically enriched miRNAs, suggesting that miRNAs may be processed locally at synapse and this processing may be aberrant in MDD brain. Altogether, our findings add a new dimension to understanding MDD pathogenesis. As suggested earlier, the shift in miRNAs may be due to altered expression and/or functions of miRNA biogenesis machinery at synapse. The enzymes and co-factors that are involved in miRNA biogenesis may possibly serve as potential therapeutic targets for future drug development in the treatment of MDD.

**FUNDING AND DISCLOSURES**
This work was supported by the National Institutes of Health (R01MH082802; R01MH101890; R01MH100616; R01MH107183; R01MH118884) to YD. The authors report no other financial interests or potential conflicts of interest.

**AUTHOR CONTRIBUTIONS**
YY and BR performed the experiment, analyzed the data, and drafted the manuscript. YD conceptualized the project, co-wrote and edited the manuscript.

**ADDITIONAL INFORMATION**
Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41386-020-00861-y).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**REFERENCES**
1. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8:2861.
2. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Snacliptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49.
3. Park CS, Gong R, Stuart J, Tang SJ. Molecular network and chromosomal clustering of genes involved in synaptic plasticity in the hippocampus. J Biol Chem. 2006;281:30195–211.
4. Roy B, Wang Q, Palkovits M, Faludi G, Dwivedi Y. Altered miRNA expression network in locus coeruleus of depressed suicide subjects. Sci Rep. 2017;7:14387.
5. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Disc. 2014;13:622–38.
6. Dwivedi Y, Roy B, Lugli G, Rizavi H, Zhang H, Smalheiser NR. Chronic corticosterone-mediated dysregulation of microRNA network in prefrontal cortex of rats: relevance to depression pathophysiology. Transl Psychiatry. 2015;5:e682.
7. Roy B, Dunbar M, Shelton RC, Dwivedi Y. Identification of microRNA-124-3p as a putative epigenetic signature of major depressive disorder. Neuropsychopharmacology. 2017;42:864–75.
8. Im HL, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neuropsychopharmacology. 2017;42:325–34.
9. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS ONE. 2012;7:e33201.
10. Lugli G, Larson J, Demars MP, Smalheiser NR. Primary microRNA precursor transcripts are localized at post-synaptic densities in adult mouse forebrain. J Neurochem. 2012;123:459–66.
11. Lugli G, Torvik VI, Larson J, Smalheiser NR. Expression of microRNAs and their precursors in synaptic fractions of adult mouse forebrain. J Neurochem. 2008;106:650–61.
12. Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR. Dicer and elf2c are enriched at postsynaptic densities in adult mouse brain and are modified by neuronal activity in a calpain-dependent manner. J Neurochem. 2005;94:896–905.
13. Bicker S, Kudhavyderbiev S, Weiss K, Zocher K, Baumeister S, Schratt G. The DEAH-box helicase DHX36 mediates dendritic localization of the neuronal precursor-microRNA-134. Genes Dev. 2013;27:2991–4.
14. Hu Z, Yu D, Gu QH, Yang Y, Tu K, Zhu J, et al. miR-191 and miR-135 are required for long-lasting spine remodelling associated with synaptic long-term depression. Nat Commun. 2014;5:3263.
15. Hu Z, Zhao J, Hu T, Luo Y, Zhu J, Li Z. miR-501-3p mediates the activity-dependent regulation of the expression of AMPA receptor subunit GluA1. J Cell Biol. 2015;208:949–59.
16. Koenigs M, Giafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behavioural Brain Res. 2009;201:239–43.
17. Miller EK, Cohen JD. An integrating theory of prefrontal cortex function. Ann Rev Neurosci. 2001;24:167–202.
18. Gyryak A, Patenaude B, Korgaonkar MS, Grieve SM, Williams LM, Etkin A. Imbalance of glutamatergic neurotransmission in frontoparietal network predicts remission to antidepressants in patients with major depression. Biol Psychiatry. 2016;79:274–81.
19. Sullivan RM, Gratton A. Prefrontal cortical regulation of hypothalamic-pituitary-adrenal function in the rat and implications for psychopathology: side matters. Psychoneuroendocrinology. 2002;27:99–114.
20. Pulopulos MM, Schmaussner M, De Smet S, Vanderhasselt MA, Baliano S, Venero C, et al. The effect of HF-ITMS over the left DLPFC on stress regulation as measured by cortisol and heart rate variability. Horm Behav. 2020;124:104830.
21. Nagy C, Maitra M, Tanti A, Suderman M, Theroux JF, Dalovi MA, et al. Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nat Neurosci. 2020;23:771–81.
22. Zalcman S, Endicott J. Diagnostic evaluation after death. Rockville, MD: National Institute of Mental Health, Neuroscience Research Branch; 1983.
23. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry. 1992;49:624–9.
24. Smalheiser NR, Collins BJ. Coordinate enrichment of cranin (dystroglycan) subunits in synaptic membranes of sheep brain. Brain Res. 2000;887:469–71.
25. Langmead B. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinforma. 2010;Chapter 11:Unit 11.7.
26. Robinson MD, Oshlack A. Scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11:R25.
27. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:3639–40.
28. Dwemp H, Getz N, miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12:697.
29. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–52.
30. Ge SX, Jung D, Yao R. ShinyG0: a graphical enrichment tool for animals and plants. Bioinformatics. 2020;36:2628–9.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;205:402–8.
32. Smalheiser NR. The RNA-centred view of the synapse: non-coding RNAs and synaptic plasticity. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130504.
33. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med. 1998;49:341–61.
34. Davidson RJ, Pizzagalli D, Smyth GK, edger: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:3639–40.
35. Gyurak A, Patauaneva B, Korgaonkar MS, Grieve SM, Williams LM, Etkin A. Frontoparietal activation during response inhibition predicts remission to antidepressants in patients with major depression. Biol psychiatry. 2016;79:274–81.

Y Yoshino et al.
910

38. Langenecker SA, Kennedy SE, Guidotti LM, Briceno EM, Own LS, Hooven T, et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry. 2007;62:1272–80.

39. Cabello-Arreola A, Ho AM, Ozderm A, Cuellar-Barboza AB, Kucukuy MU, Heppelmann CJ, et al. Differential dorsolateral prefrontal cortex proteomic profiles of suicide victims with mood disorders. Genes. 2020;11:256.

40. Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA, et al. Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci: Off J Soc Neurosci. 2007;27:13329–40.

41. Wang Q, Divviedi Y. Transcriptional profiling of mitochondria associated genes in prefrontal cortex of subjects with major depressive disorder. World J Psychiatry. 2017;8:592–603.

42. Zhao J, Verwer RWN, Gao SF, Qi XR, Lucassen PJ, Kessels HW, et al. Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide. J Psychiatr Res. 2018;102:261–74.

43. Divviedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide-3-kinase signaling in postmortem brain of suicide subjects. Biol Psychiatry. 2010;67:1017–25.

44. Divviedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Aberrant extracellular signal-regulated kinase (ERK1/2) signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol / Off Sci J Collegium Int Neuropsychopharmacolog. 2009;12:1337–54.

45. Divviedi Y, Pandey GN. Elucidating biological risk factors in suicide: role of protein kinase A. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:831–42.

46. Mody HR, Hung SW, Pathak RK, Griffin J, Cruz-Monserrate Z, Govindarajan R. miR-202 diminishes TGFbeta receptors and attenuates TGFbeta1-induced EMT in pancreatic cancer. Mol Cancer Res. 2017;15:1029–39.

47. Tang CZ, Yang JT, Liu QH, Wang YR, Wang WS. Up-regulated miR-192-5p expression rescues cognitive impairments and restores neural function in mice with depression via the Fbn1-mediated TGF-beta1 signaling pathway. FASEB J. 2019;33:606–18.

48. Yang X, Cai JB, Peng R, Wei CY, Lu JC, Gao C, et al. The long noncoding RNA 3-deoxyadenosine (m6dA) drives activity-induced gene expression and is a regulator of mitochondrial function. J Cell Physiol. 2019;234:12051–60.

49. Li X, Zhao Q, Wei W, Lin Q, Magnan C, Emami MR, et al. The DNA modification 5-(N2-propyl)cytosine (m5pc) functions as a hypomethylating agent and is selectively activated in cancer cells. Proc Natl Acad Sci U S A. 2011;108:13806–11.

50. Krieglstein K, Zheng F, Unsicker K, Alzheimer C. More than being protective: the DNA methylation changes reflecting altered TGFbeta signaling in human brain of suicide subjects. Brain. 2005;128:1648–60.

51. Li X, Zhao Q, Wei W, Lin Q, Magnan C, Emami MR, et al. The DNA modification 5-(N2-propyl)cytosine (m5pc) functions as a hypomethylating agent and is selectively activated in cancer cells. Proc Natl Acad Sci U S A. 2011;108:13806–11.

52. Smalheiser NR, Lugli G, Rizavi HS, Zhang H, Duarte JM, Goncalves FQ, Real J, et al. Depression as a glial-based synaptic dysfunction. Front Cell Neurosci. 2015;9:521.

53. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:1971–24.

54. Divviedi Y, Rizavi HS, Roberts RC, Conley RR, Tamminga CA, Pandey GN. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem. 2001;77:916–28.

55. Gutierrez-Mecinas M, Trollope AF, Collins A, Morrett H, Hesketh SA, Kersante F, et al. Long-lasting behavioral responses to stress involve a direct interaction of glucocorticoid receptors with ERK1/2-MSK1-Elk-1 signaling. Proc Natl Acad Sci USA. 2011;108:13806–11.

56. Revest JM, Di Blasi F, Kitchener P, Rouge-Pont F, Desmedt A, Turiault M, et al. The MAPK pathway and Erk-1 mediated stress-related behavioral effects of glucocorticoids. Nat Neurosci. 2005;8:664–72.

57. Apazoglu K, Farley S, Gorgievski V, Belneau R, Lopez JP, Grenier J, et al. Anti-depressive effects of targeting ELK-1 signal transduction. Nat Med. 2018;24:591–7.

58. Caraci F, Spampinato SF, Morgese MG, Tasciaga F, Salvaterra MG, Giambironte MC, et al. Neurobiological links between depression and AD: the role of TGF-beta signaling as a new pharmacological target. Pharm Res. 2018;35:734–44.

59. Fan C, Zhu X, Song Q, Wang P, Liu Z, Yu SY. mir-134 modulates chronic stress-induced structural plasticity and depression-like behaviors via downregulation of Limk1/coflin signaling in rats. Neuropharmacology. 2018;131:366–74.

60. Divviedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60:273–82.

61. Xie Y, Wang L, Xie Z, Zeng C, Shu K. Transcriptomics evidence for common pathways in human major depressive disorder and glioblastoma. Int J Mol Sci. 2018;19:234.

62. Guo L, Zhao Y, Zhang H, Yang S, Chen F. Integrated evolutionary analysis of human miRNA gene clusters and families implicates evolutionary relationships. Gene. 2014;534:24–32.

63. Smalheiser NR, Lugli G, Rizavi HS, Zhang H, Cook EH, Divviedi Y. Expression of microRNAs and other small RNAs in prefrontal cortex in schizophrenia, bipolar disorder and depressed subjects. PLoS ONE. 2014;9:e86469.

64. Kim HH, Kim P, Phay M, Yoo S. Identification of precursor microRNAs within distal axons of sensory neuron. J Neurochem. 2015;134:193–9.

65. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.

66. © The Author(s) 2020

67. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party materials in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

68. © The Author(s) 2020